CN107912776A - A kind of edible composition and its application for aiding in reducing the glycemic index of food - Google Patents
A kind of edible composition and its application for aiding in reducing the glycemic index of food Download PDFInfo
- Publication number
- CN107912776A CN107912776A CN201610879062.3A CN201610879062A CN107912776A CN 107912776 A CN107912776 A CN 107912776A CN 201610879062 A CN201610879062 A CN 201610879062A CN 107912776 A CN107912776 A CN 107912776A
- Authority
- CN
- China
- Prior art keywords
- food
- edible composition
- oil
- composition
- oligofructose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 79
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000002641 glycemic effect Effects 0.000 title claims abstract description 12
- 210000004369 blood Anatomy 0.000 claims abstract description 42
- 239000008280 blood Substances 0.000 claims abstract description 42
- 239000000843 powder Substances 0.000 claims abstract description 23
- 235000000346 sugar Nutrition 0.000 claims abstract description 22
- 239000004375 Dextrin Substances 0.000 claims abstract description 18
- 229920001353 Dextrin Polymers 0.000 claims abstract description 18
- 235000019425 dextrin Nutrition 0.000 claims abstract description 18
- 235000015097 nutrients Nutrition 0.000 claims abstract description 11
- 230000000291 postprandial effect Effects 0.000 claims abstract description 10
- 150000001720 carbohydrates Chemical class 0.000 claims description 16
- 235000014633 carbohydrates Nutrition 0.000 claims description 16
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 12
- 239000011707 mineral Substances 0.000 claims description 12
- 235000010755 mineral Nutrition 0.000 claims description 12
- 229940088594 vitamin Drugs 0.000 claims description 10
- 239000011782 vitamin Substances 0.000 claims description 10
- 229930003231 vitamin Natural products 0.000 claims description 9
- 235000013343 vitamin Nutrition 0.000 claims description 9
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229920001503 Glucan Polymers 0.000 claims description 6
- 239000002994 raw material Substances 0.000 claims description 6
- 150000001875 compounds Chemical class 0.000 claims description 5
- 235000018102 proteins Nutrition 0.000 claims description 5
- 102000004169 proteins and genes Human genes 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- 235000019486 Sunflower oil Nutrition 0.000 claims description 4
- 239000000828 canola oil Substances 0.000 claims description 4
- 235000019519 canola oil Nutrition 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 4
- 239000003549 soybean oil Substances 0.000 claims description 4
- 235000012424 soybean oil Nutrition 0.000 claims description 4
- 239000002600 sunflower oil Substances 0.000 claims description 4
- 238000006243 chemical reaction Methods 0.000 claims description 3
- 230000003028 elevating effect Effects 0.000 claims description 3
- 108010011756 Milk Proteins Proteins 0.000 claims description 2
- 102000014171 Milk Proteins Human genes 0.000 claims description 2
- 235000019484 Rapeseed oil Nutrition 0.000 claims description 2
- 108010073771 Soybean Proteins Proteins 0.000 claims description 2
- 108010046377 Whey Proteins Proteins 0.000 claims description 2
- 235000013399 edible fruits Nutrition 0.000 claims description 2
- 235000021239 milk protein Nutrition 0.000 claims description 2
- 235000008390 olive oil Nutrition 0.000 claims description 2
- 239000004006 olive oil Substances 0.000 claims description 2
- 239000003813 safflower oil Substances 0.000 claims description 2
- 235000019710 soybean protein Nutrition 0.000 claims description 2
- 235000021119 whey protein Nutrition 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 abstract description 16
- 210000001015 abdomen Anatomy 0.000 abstract description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 26
- 239000008103 glucose Substances 0.000 description 26
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 26
- 239000000047 product Substances 0.000 description 24
- 230000002218 hypoglycaemic effect Effects 0.000 description 21
- 208000013016 Hypoglycemia Diseases 0.000 description 17
- 102000004877 Insulin Human genes 0.000 description 13
- 108090001061 Insulin Proteins 0.000 description 13
- 229940125396 insulin Drugs 0.000 description 13
- 235000013325 dietary fiber Nutrition 0.000 description 12
- 229930091371 Fructose Natural products 0.000 description 11
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 11
- 229930006000 Sucrose Natural products 0.000 description 11
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 11
- 229960002737 fructose Drugs 0.000 description 11
- 239000005720 sucrose Substances 0.000 description 11
- 239000005715 Fructose Substances 0.000 description 10
- 230000000694 effects Effects 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 235000012054 meals Nutrition 0.000 description 8
- 229920002472 Starch Polymers 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 235000019698 starch Nutrition 0.000 description 7
- 239000008107 starch Substances 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 235000019197 fats Nutrition 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 5
- 235000005911 diet Nutrition 0.000 description 5
- 230000037213 diet Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 4
- 240000000111 Saccharum officinarum Species 0.000 description 4
- 235000007201 Saccharum officinarum Nutrition 0.000 description 4
- 239000011575 calcium Substances 0.000 description 4
- 229910052791 calcium Inorganic materials 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- 229910052804 chromium Inorganic materials 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 229940125532 enzyme inhibitor Drugs 0.000 description 4
- 239000002532 enzyme inhibitor Substances 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000003304 gavage Methods 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000010241 blood sampling Methods 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 102000038379 digestive enzymes Human genes 0.000 description 3
- 108091007734 digestive enzymes Proteins 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 229920002498 Beta-glucan Polymers 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 2
- 240000008892 Helianthus tuberosus Species 0.000 description 2
- 235000003230 Helianthus tuberosus Nutrition 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 229920001202 Inulin Polymers 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 240000003186 Stachytarpheta cayennensis Species 0.000 description 2
- 235000009233 Stachytarpheta cayennensis Nutrition 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
- 206010000059 abdominal discomfort Diseases 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 238000013329 compounding Methods 0.000 description 2
- 235000008504 concentrate Nutrition 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000021245 dietary protein Nutrition 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 201000001421 hyperglycemia Diseases 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000006362 insulin response pathway Effects 0.000 description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 2
- 229940029339 inulin Drugs 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000008520 organization Effects 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 210000000496 pancreas Anatomy 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229960003975 potassium Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000008542 thermal sensitivity Effects 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000011701 zinc Substances 0.000 description 2
- 229910052725 zinc Inorganic materials 0.000 description 2
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- 239000001763 2-hydroxyethyl(trimethyl)azanium Substances 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 235000019743 Choline chloride Nutrition 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 239000011665 D-biotin Substances 0.000 description 1
- 235000000638 D-biotin Nutrition 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- SRBFZHDQGSBBOR-HWQSCIPKSA-N L-arabinopyranose Chemical compound O[C@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-HWQSCIPKSA-N 0.000 description 1
- 201000010538 Lactose Intolerance Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- FLDFNEBHEXLZRX-DLQNOBSRSA-N Nystose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(O[C@@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 FLDFNEBHEXLZRX-DLQNOBSRSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- FPIPGXGPPPQFEQ-BOOMUCAASA-N Vitamin A Natural products OC/C=C(/C)\C=C\C=C(\C)/C=C/C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-BOOMUCAASA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 229930003448 Vitamin K Natural products 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 229940077731 carbohydrate nutrients Drugs 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- -1 carbon water Compound Chemical class 0.000 description 1
- 229960003178 choline chloride Drugs 0.000 description 1
- SGMZJAMFUVOLNK-UHFFFAOYSA-M choline chloride Chemical compound [Cl-].C[N+](C)(C)CCO SGMZJAMFUVOLNK-UHFFFAOYSA-M 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 235000019007 dietary guidelines Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 235000021433 fructose syrup Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 150000002584 ketoses Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 231100000989 no adverse effect Toxicity 0.000 description 1
- FLDFNEBHEXLZRX-UHFFFAOYSA-N nystose Natural products OC1C(O)C(CO)OC1(CO)OCC1(OCC2(OC3C(C(O)C(O)C(CO)O3)O)C(C(O)C(CO)O2)O)C(O)C(O)C(CO)O1 FLDFNEBHEXLZRX-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000003014 reinforcing effect Effects 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 235000019168 vitamin K Nutrition 0.000 description 1
- 239000011712 vitamin K Substances 0.000 description 1
- 150000003721 vitamin K derivatives Chemical class 0.000 description 1
- 229940045997 vitamin a Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 229940046008 vitamin d Drugs 0.000 description 1
- 229940046010 vitamin k Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of edible composition and its application for aiding in reducing the glycemic index of food, the edible composition, it includes oligofructose and resistant dextrin, and oligofructose and the weight ratio of resistant dextrin are 1：1‑9.Said composition can be added in food such as nutrient powder with 5 15% mass percents, and obtained food has the function that to adjust postprandial blood sugar, and diarrhea rate is low, and belly comfort level is good, in addition, good in taste, viscosity is relatively low, is easy to drink.
Description
Technical field
The present invention is that it includes the oligofructose of special ratios on a kind of edible composition for aiding in reducing glycemic index
With resistant dextrin.In addition, the present invention also on it is described be with composition prepare with hypoglycemia patient food in
Using and a kind of preparation-obtained hypoglycemia patient nutrient powder.
Background technology
Glucose resultant index (GI, also known as glycemic index) is the index for describing food physiologic parameters, is expressed not
There is the new concept of Different Effects to blood glucose with classes-carbohydrates.Using glucose syrup GI values as 100%, according to the big I of GI values
Rich carbo is divided into different brackets：GI values<55% food is considered as low GI foods, GI values 55%~
Between 70% scope is high GI food more than 70% for middle GI foods, GI values.Research shows that low GI foods can slowly be inhaled
Receive, continuous energy release, help to maintain the definition and application of glycaemic homeostasis, prevention diabetes, therefore food GI are also gradual to obtain
To the confirmation and attention of the World Health Organization (WHO) and FAO (Food and Agriculture Organization of the United Nation) (FAO).
Different foods are also different to the stimulation of insulin due to the speed difference for being converted into glucose.And pancreas islet
Element secretion and body are to influence two big factors of blood glucose on the sensitiveness of insulin.The secretion of insulin is directly subject to glucose
Regulation and control.Largely giving the glucose easily absorbed can be such that insulin quickly raises.Research points out that a large amount of secretions of insulin can cause
Hyperinsulinemia, long-term hyperinsulinemia are to cause one of insulin resistance, diabetes, factor of cardiovascular disease again.But
It is that the content for being related to insulin is relatively fewer in the research of conventional food GI.
Influence of the food to blood glucose is not only related with the content of carbohydrate, source, type also with carbohydrate,
Physical behavior, chemical constitution, processing method, storage requirement etc. are related, so even being different product made of same raw material
Different blood glucose responses can also be produced, there is different GI values.And food industry passes through reasonably combined, processing carbohydrate
Preferable GI products are likely to be obtained, and carry out autotelic production.
At present in field of food, to reduce food product glycemic index, mainly food is reduced by following several ways
GI values：1st, food protein and fat content are improved so as to reduce food carbohydrate content, or increase blood insulin
Content reduces food GI values；2nd, a part of carbohydrate is substituted using fructose or indigestibility starch, because fructose absorbs
Enter not direct elevating blood glucose content after blood and reduce food GI values, and indigestibility starch is nondigestible due to oneself
Property, slow down the blood glucose after eating and rise；3rd, play the role of reducing food GI values using the sticky diet fiber composition such as colloid；
4th, using sucrose digestive enzyme inhibitor；5th, the processing to raw food material is reduced, it is kept complete structure, increase digests difficulty,
Extend digestion time.6th, the complex compound of chromium and chromium is added.But these modes all have its limitation：Unmeasured raising
Food protein and fat content can undoubtedly increase blood lipids and kidney burden, stimulate insulin secretion, merely by this
It is also without actual nutritional significance that mode, which reduces blood glucose response,；Fructose is used to substitute part carbon because the GI values of itself are relatively low
Hydrate, but from the angle of science, fructose is other using carbohydrate for substituting, and amount is no more than total energy
The 12% of amount, human body and zoopery are shown, high fructose syrup can cause fatty excessive precipitation, fatty liver denaturation, hyperglycaemia, painstaking effort
Pipe disease etc.；Indigestibility starch may not be utilized causes food to provide the energy needed for body completely, while mouthfeel is not
It is good；The larger dietary fiber of addition viscosity come increase system viscosity delay to digest and assimilate mouthfeel can be caused bad and have a stomach upset and
And it is difficult to reach dietary fiber recommendation 25-30g/ days；It is incomplete that energy utilization is also resulted in using sucrose digestive enzyme inhibitor,
Simultaneously as excessive sucrose is enriched with enteron aisle, osmotic pressure increases, and triggers diarrhea；The processing to food materials is reduced, mouthfeel can be become
Difference, it is difficult to be esthetically acceptable to the consumers and be used to aid in stabilizing blood sugar to be eaten for a long time, some results even in abdominal discomfort；Chromium
Reinforcing is effective to the patient for having chromium deficiency.
On current market it can be seen that low GI powder group food product it is more, be mostly increase lipoprotein content, make
On the basis of the fructose of part, while change food using dietary fiber and digest and assimilate process, to reduce food GI values.Such as
The good SR of Abbott Laboratories' benefit power (albumen energizes ratio 20%, fatty energy supply ratio 32%), the good meals of nest in Taiwan fit sugared (albumen energy supply ratio
Example 18.6%, fatty energy supply ratio 40%), Hua Ruiruidai (albumen energizes ratio 15%, fatty energy supply ratio 32%).However,
In these low GI powder group food products, fatty energy supply ratio alreadys exceed Chinese residents meals recommendation 30%, despite with list
Based on unrighted acid, still result in and blood fat problem is brought while controlling blood glucose, and blood fat is equally patient of diabetes
Person needs the index paid close attention to, such long-term use of product can bring blood fat risk and then trigger cardio cerebrovascular affection；In addition, this
If fructose content is higher (fructose energizes ratio more than 12% in the product of such as Hua Rui) in class product, long-term use is also led to
A series of side effects.
The prior art also play the role of document report difference dietary fiber composition can play it is hypoglycemic.
CN103053903A discloses a kind of compound functional sugar for having and reducing glucose resultant index, it includes L- Ah
Uncle's sugar, functional oligose, dietary fiber and mulberry-leaf extract are drawn, wherein, L-arabinose and mulberry-leaf extract can press down
Invertase processed so that sucrose is not digested and assimilated fully, which influences metabolism of the sugarcane sugar and starch in human body, can
To reduce the blood glucose response of sugarcane sugar and starch, Area under the curve of blood glucose is become GI values that are gentle, reducing sugarcane sugar and starch, at the same time
The secretion of insulin can be reduced, area under insulin curve is become gentle, and shows to reduce insulin and blood glucose response
Cumulative area ratio under curve, finally plays the effect reduced with sucrose with postprandial blood sugar when eating, this to produce containing sucrose
The energy of product is not completely absorbed, and may be used as in snack sweets, ensures taste, and do not take in excessive sugar and energy.So
And the compound functional sugar is only applicable to need the food using sucrose, there is certain limitation using upper；In addition, wherein use
Sucrose digestive enzyme inhibitor can cause food energy, and using not exclusively, simultaneously as excessive sucrose is enriched with enteron aisle, osmotic pressure increases
Height, may trigger diarrhea.
CN101193561B discloses a kind of granulated diet fiber composition, it is included gathers from 60% to 90% Portugal's sweet dew
Sugar, from 5% to 20% xanthans and from 5% to 20% alginates, said composition can be used for food with 2%~30% amount, have
Play the role of promoting full sense, promote weight loss, reduce blood-sugar content or reduce blood cholesterol level.But this few class meals
Food fiber if it is desired to reach Chinese residents dietary fiber recommendation (referring to《Chinese residents dietary guidelines (2016)》), it will lead
Reason excessively causes product to have higher viscosity to use, and product viscosity is excessive, and mouthfeel is bad.
Therefore, how to ensure food mouthfeel, provide a kind of food of hypoglycemia patient on the premise of viscosity performance,
It is industry problem urgently to be resolved hurrily.
The content of the invention
It is an object of the present invention to provide a kind of edible composition for aiding in reducing the glycemic index of food, it is used to make
The food of standby hypoglycemia patient, can guarantee that food mouthfeel, viscosity performance are substantially unaffected.
Another object of the present invention is to provide the edible composition in the food of hypoglycemia patient is prepared
Using.
Another object of the present invention is to provide a kind of to have hypoglycemia patient comprising the edible composition
Food, especially a kind of powder state nutritional supplement based food.
On the one hand, the present invention provides a kind of edible composition for aiding in reducing the glycemic index of food, it includes oligomeric fruit
Sugar and resistant dextrin, and oligofructose and the weight ratio of resistant dextrin are 1：1-9.
In the present invention, in addition to especially indicating, the ratio, content are part by weight and content.
Oligofructose is also known as fructooligosaccharide, is to pass through the fructose in β (2-1) glycosidic bonds and sucrose by 1~3 fructosyl
Base junction symphysis into ketose, Nystose and sugarcane sugar etc. mixture.60-70 grams is there are about in 100 grams of dry weight jerusalem artichokes
Inulin, inulin are by linear β -2, the levulan of 1- glucosides chain links, its end is a sucrose base.Therefore using jerusalem artichoke powder as original
Material uses synanthrin restriction endonuclease hydrolysis, and oligofructose can be finally obtained through refined.Oligofructose, which is removed, has general utility functions oligosaccharide
Physicochemical properties outside, most noticeable physiological property is that it can be obviously improved microbial population ratio in enteron aisle, it is
The activation and proliferation factor of enteral Bifidobacterium, can reduce and suppress the generation of enteral corrupt substance, suppress the growth of harmful bacteria,
Adjust enteron aisle inner equilibrium；It can promote the absorption and utilization of trace elements iron, calcium, to prevent osteoporosis；Toxin for liver can be reduced
Element, the organic acid of anticancer can be generated in intestines, there is significant preventing cancer function；And pure taste is sweet and dilitious.Oligofructose is benefit
Raw member, while there is preferable hypoglycemic effect, but excessive use is easy to cause diarrhea (more than 15-17g/ days).
Resistant dextrin is process by starch, is that the indigestibility component industrial technology extraction process that will bake dextrin is simultaneously smart
A kind of Low Caloric Polydextrose formed is refined, belongs to low molecule water-soluble dietary fiber.The Aqueous Solution Viscosity of resistant dextrin is very low, and
And k value is small with change caused by shear rate and temperature change.This is helpful for Product processing.Resistance is pasted
Essence is with good hypoglycemic effect.Its mechanism is probably to promote enteron aisle glucagon-like peptide (GLP-1) increase product
Indigestible, extend Passage time.Intake resistant dextrin can cause hypoglycemia (glucose response=25) and blood pancreas islet
Element reaction (insulin response=13) (Donazzolo etc., 2003).Clinical data proves that a meal is taken 5g resistant dextrins and had definitely
Effect, if being used for full nutritional supplement, eats 6 times a day, and intake total amount reaches 30g.Since patient can be taken the photograph by diet
Other dietary fibers entered, the dietary fiber caused one day exceed meals recommendation 30g/ days, do not meet dietary fiber diversity.
So we need reduction resistant dextrin usage amount to reach hypoglycemic effect at the same time.
Above two dietary fiber is compounded according to special ratio in the present invention, it is found that the composition after its compounding is used to add
Be added in food, good control blood glucose can be played the role of on the premise of diarrhea is not produced as far as possible, and to product mouthfeel,
Viscosity performance has no adverse effect substantially, and can avoid being largely used to drink in type and tube feed product causes mouthfeel bad and poor fluidity
Situation occur.The edible composition of the present invention can be used as with special function of polysaccharide and the special offer full nutrition of diabetic
Dedicated composition, while eaten suitable for lactose intolerant patient.
Specific embodiment according to the present invention, in edible composition of the invention, the weight of oligofructose and resistant dextrin
Amount is than being 1：1-9, is preferably 1：1-4.
Specific embodiment according to the present invention, edible composition of the invention further include the oatmeal rich in glucan,
The weight ratio of the oatmeal and oligofructose rich in glucan is 1-5：1.More specifically, the oat rich in glucan
Oat beta glucan content more than 23% in powder.The addition of oatmeal rich in glucan can aid in further reducing food GI
Value.Wherein, oat beta-glucan requirement is complete long chain polysaccharides.
On the other hand, have present invention also offers the edible composition in preparation and delay postprandial blood sugar elevating effect
It is low it is glycemic generation index food particularly powder based food in application.
Specific embodiment according to the present invention, the edible composition are to be added to food with 5-15% mass percents
In.
On the other hand, present invention also offers a kind of food with hypoglycemia patient, including 5-15% matter
Measure the edible composition of the present invention of percentage.
Specific embodiment according to the present invention, the food provided by the invention with hypoglycemia patient are sought to be a kind of
Powder is supported, on the basis of the gross weight of the nutrient powder, its raw material composition includes：
Protein 10%-30%；
Fatty 10%-30%；
Carbohydrate 30%-70%；
Composition 5%-15%；
Vitamin 1.0-5 ‰；
Mineral matter (in terms of the mineral matter elements such as calcium, iron, zinc) 0.5-5%.
Specific embodiment according to the present invention, in the food with hypoglycemia patient of the invention, the albumen
One or more of the matter in milk protein concentrate, Whey Protein Concentrate, soybean protein.
Specific embodiment according to the present invention, in the food with hypoglycemia patient of the invention, the fat
One kind or more in high oleic sunflower oil, soybean oil, Canola Oil, rapeseed oil, safflower seed oil, olive oil
Kind；Preferably, it is adipose-derived in high oleic sunflower oil, soybean oil, Canola Oil according to 4-7：1-5：1-3 ratios are answered
Match somebody with somebody, it is ensured that rational saturated fat, monounsaturated fatty acids, the ratio of polyunsaturated fatty acid so that produced after consumable products
Raw less blood fat burden.
Specific embodiment according to the present invention, in the food with hypoglycemia patient of the invention, the carbon water
Compound, which derives from, has water miscible carbohydrate.
Specific embodiment according to the present invention, in the food with hypoglycemia patient of the invention, vitamin comes
Source meets special diet vitamin source requirement.Mineral origin is mineral salt, and source meets special diet mineral matter
Source requires.Wherein, the source of sodium and potassium uses citrate sources, and is accordingly matched, and ensures the amount of sodium and potassium, together
Shi Zuowei protein stabilisers.
The content of formula vitamin and mineral can be designed substantially according to Chinese residents meals recommendation.Research is found
Crowd with higher angiocardiopathy risk suitably increases vitamin c intake, can reduce painstaking effort and suffer from the disease generation
Risk.And hyperglycemia population is exactly angiocardiopathy group of people at high risk.So in food formula of the invention, it can additionally strengthen dimension
Raw element C, it is preferable that content of the vitamin C in the food with hypoglycemia patient of the present invention is more than 200mg/100g.
Specific embodiment according to the present invention, can also wrap in the food with hypoglycemia patient of the invention
Include：The common food additive such as essence and flavoring agent.
The food with hypoglycemia patient of the present invention, can be according to the compounding group of wherein oligofructose and resistant dextrin
Compound conversion for people often eat (50-60g finished products) eat 1.7-6g designs, you can have the function that to adjust postprandial blood sugar, and overall effect
Fruit is more excellent.Oligofructose dosage is less than the risk dosage for causing diarrhea, and it is the every canteen 0.4-3g of people to convert.
In the food with hypoglycemia patient of the present invention, the use of each raw material should all meet relevant laws and regulations and
The requirement of standard.
The advantageous effects that the edible composition and the food of the present invention can have：
1st, edible composition of the invention can energize ratio 10-30% in food system albumen, and fatty energy supply ratio is small
In 30%, fructose is controlled on the premise of energizing within ratio 12%, product blood glucose value is further reduced, so as to take for a long time
With for Blood sugar management.Animal test results show that effect is better than similar product.Zoopery glycemic peaks, postprandial blood sugar face
Product, GI value Testing index all have a clear superiority.
2nd, serum insulin level is influenced relatively low.
3rd, using in food product, good in taste, viscosity is relatively low, is easy to drink.
4th, using product viscosity in food product, is had substantially no effect on, good fluidity, is used to manage after ensureing nutrient powder dissolving
Raise.
5th, without using disaccharide enzyme inhibitor, energy that food contains can be all of, just with speed be slow.
6th, diarrhea rate is low, and belly comfort level is good.
Embodiment
The following example is only to be illustrated, not intended to limit the scope of the present invention.Those skilled in the art can
By the exposure of the present invention, appropriate change and amendment are made in the scope of the spirit without departing substantially from the present invention.
" vitamin and minerals " in each embodiment and comparative example are commercially available multi-vitamins and composite mineral matter, wherein,
Vitamin include choline chloride, vitamin A, vitamin D, vitamin E, vitamin K, vitamin C, vitamin B1, vitamin B2,
Vitamin B6, vitamin B12, niacinamide, folic acid, D-VB5 calcium, D-Biotin；Mineral matter include potassium citrate, sodium citrate,
Magnesium, calcium, iron, zinc, manganese, copper, iodine, the various saline sources of selenium.
Embodiment 1
The sample 1,2 and contrast sample 1-5 of the present invention is prepared according to formula as below.
Each sample preparation method：
Albumen powder, dextrin, vegetable oil, vitamin, mineral matter are dissolved in 45 DEG C of water in sequence, form 20%-
25% solution, is stirred under vacuum and is uniformly mixed.If it is necessary, adjust pH value using 1% KOH or NaOH solution.According to level-one
Homogeneous 100bar, double-stage homogenization 40bar homogeneous, 60 DEG C or so are concentrated in vacuo to more than 45%, sterilize, and be in inlet air temperature
The spray drying of 150 DEG C of -180 DEG C of sections, finally dry-mixed part thermal sensitivity raw material in proportion, forms final nutrient powder.
Zoopery measure formula blood glucose response index of correlation：
The fasting 20h before experiment, takes after fasting blood gavage to give tested material, using the dense of carbohydrate in tested material
Degree is 10%, is 2.0g/kgbw using the dosage of giving of carbohydrate, after gavage 30min, 60min,
90min, 120min and 180min take big rat-tail blood, take serum to carry out the detection of blood glucose value after 6000rpm centrifugations 10min.
The fasting 20h before experiment, takes after fasting blood gavage to give tested material, using the dense of carbohydrate in tested material
Degree is 10%, is 2g/kgbw using the dosage of giving of carbohydrate, after gavage 30min, 60min and
120min takes big rat-tail blood, takes serum to carry out the detection of insulin after 6000rpm centrifugations 10min.
GI values detect：
Experiment the previous day unifies dinner, the intake of control high protein, fat and dietary fiber food, fasting 10h before experiment
And avoid strenuous exercise, smoking, drink.Experimental day early morning walks to laboratory, and peace and quiet are seated on chair at least 5 minutes, empty
It is oral (to be dissolved in reference to food glucose 50g in 250ml pure water) after abdomen venous blood sampling 3ml, take, will start in 10min
The oral time is denoted as 0min, and venous blood sampling 3ml is distinguished in subsequent 15,30,45,60,90,120,180,240min.Taken
Blood sample stands 1h, and 3000 turns centrifuge serum for 10 minutes and measure blood glucose and insulin level, subject per respectively
Satiety record sheet is filled in after blood sampling at once.
Other foods and medicine must not be fed during experiment, can drink water 100-200ml, can be movable on a small quantity.
After glucose tolerance, week about, each sample is repeated the above process respectively, measure respectively equivalent to containing
The sample to be tested of 50g carbohydrate is dissolved in 250ml pure water, remaining operation is same as above.
The sample 1,2 of the present invention and the postprandial blood sugar and GI value measurement results of contrast sample 1-5 see the table below.
The experimental result of above-mentioned sample is drawn, the composition of the present invention is used in complete nourishing powder product, sample one and sample
Product two on the premise of fructose uses no more than 8g/100g, enable to the Postprandial peak glucose of product, postprandial blood sugar area,
Insulin response and GI values are in preferable horizontal.
Viscosity test and mouthfeel and Incidence of Diarrhea investigate experiment：Viscosity test is carried out to each sample, and evaluates its mouthfeel,
Investigate Incidence of Diarrhea.
Viscosity measurement：58g nutrient powders, are dissolved in 190ml warm water, obtain 250ml nutrient solutions.Use brookfield viscosity
Count and nutrition fluid viscosity is detected under room temperature.
Mouthfeel and Incidence of Diarrhea evaluation method：By the volunteer of 50 40-50 Sui, each taking a meal amount (58g),
250ml.As the meal of generation on the one.According to volunteer's questionnaire survey, mouth feel score and diarrhea rate are recorded.Mouthfeel is using smoothness as finger
Mark, TOP SCORES are divided into 1-10 points, and more than 8 points are excellent, and 5-7 points are weight, and less than 5 points are poor.Diarrhea occurs subjective with volunteer
Experience as with and without judgement.
Experimental result is referring to following table.
| Sample 1 | Sample 2 | Contrast sample 1 | Contrast sample 2 | Contrast sample 3 | Contrast sample 4 | |
| Viscosity/centipoise | 30 | 48 | 30 | 30 | 30 | 80 |
| Mouthfeel | It is excellent | It is excellent | It is excellent | It is excellent | It is excellent | In |
| Incidence of Diarrhea | 4% | 4% | 10% | 5% | 35% | 30% |
The experimental result of above-mentioned sample is drawn, the composition of the present invention is used in complete nourishing powder product, sample 1 and sample
2 viscosity is relatively low, good in taste, Incidence of Diarrhea is relatively low.With significant advantage.
Embodiment 2
The nutrient powder of the present embodiment is prepared according to formula as below.
Albumen powder, dextrin, vegetable oil, citrate, vitamin, mineral matter are dissolved in 45 DEG C of water in sequence, shape
Into the solution of 20%-25%, it is stirred under vacuum and is uniformly mixed.According to level-one homogeneous 100bar, double-stage homogenization 40bar homogeneous, 60 DEG C
Left and right is concentrated in vacuo to 48%, sterilizes, and is spray-dried in inlet air temperature for 170 DEG C of -175 DEG C of sections, finally dry-mixed in proportion
Part thermal sensitivity raw material, forms final nutrient powder.
Postprandial blood sugar and GI values measure, viscosity test and the mouthfeel and Incidence of Diarrhea of the sample of the present embodiment investigate experiment
With embodiment 1, specific experiment result is referring to following table.
It can be seen from above-mentioned experimental result by the present invention composition be used for complete nourishing powder product in, product viscosity compared with
It is low, it is good in taste, Incidence of Diarrhea is relatively low.
Claims (10)
1. a kind of edible composition for aiding in reducing the glycemic index of food, it includes oligofructose and resistant dextrin, and oligomeric fruit
The weight ratio of sugar and resistant dextrin is 1：1-9.
2. edible composition according to claim 1, wherein, the weight ratio of oligofructose and resistant dextrin is 1：1-4.
3. edible composition according to claim 1 or 2, said composition further includes the oatmeal rich in glucan, described
The weight ratio of oatmeal and oligofructose rich in glucan is 1-5：1.
4. claims 1 to 3 any one of them edible composition is being prepared with the low blood for delaying postprandial blood sugar elevating effect
Application in the food of sugar generation index.
5. application according to claim 4, wherein, the edible composition is to be added to food with 5-15% mass percents
In product.
6. application according to claim 4, wherein, the food is powder based food.
A kind of 7. food, including claims 1 to 3 any one of them edible composition of 5-15% mass percents.
8. food according to claim 7, it is a kind of nutrient powder, on the basis of the gross weight of the nutrient powder, its raw material
Composition includes：
Protein 10%-30%；
Fatty 10%-30%；
Carbohydrate 30%-70%；
Composition 5%-15%；
Vitamin 1.0-5 ‰；
Mineral matter element meter 0.5-5%.
9. food according to claim 8, wherein,
One or more of the protein source in milk protein concentrate, Whey Protein Concentrate, soybean protein；
It is described adipose-derived in high oleic sunflower oil, soybean oil, Canola Oil, rapeseed oil, safflower seed oil, olive oil
One or more；Preferably, it is adipose-derived in high oleic sunflower oil, soybean oil, Canola Oil according to 4-7：1-5：
1-3 ratios compound；
The carbohydrate source is in water miscible carbohydrate.
10. food according to claim 8 or claim 9, the conversion of oligofructose content is people per canteen 0.4-3g in the food.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610879062.3A CN107912776A (en) | 2016-10-09 | 2016-10-09 | A kind of edible composition and its application for aiding in reducing the glycemic index of food |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610879062.3A CN107912776A (en) | 2016-10-09 | 2016-10-09 | A kind of edible composition and its application for aiding in reducing the glycemic index of food |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN107912776A true CN107912776A (en) | 2018-04-17 |
Family
ID=61891588
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610879062.3A Pending CN107912776A (en) | 2016-10-09 | 2016-10-09 | A kind of edible composition and its application for aiding in reducing the glycemic index of food |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107912776A (en) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108523134A (en) * | 2018-05-04 | 2018-09-14 | 珠海津之敦医药科技有限公司 | A kind of avenabeta glucosan Orally administered composition and its application |
| CN110179107A (en) * | 2019-07-01 | 2019-08-30 | 北京东方倍力营养科技有限公司 | A kind of complete nutritional composition improving liver function and liver fibrosis |
| CN112273440A (en) * | 2020-09-16 | 2021-01-29 | 内蒙古欧世蒙牛乳制品有限责任公司 | Low-GI composition and low-GI milk powder with blood sugar balancing effect |
| CN113951328A (en) * | 2021-11-30 | 2022-01-21 | 北安宜品努卡乳业有限公司 | A nutritional food for lowering blood sugar and reducing blood lipid, and its preparation method |
| CN115553457A (en) * | 2021-06-30 | 2023-01-03 | 杨劲松 | Food composition for regulating blood sugar metabolism |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103478527A (en) * | 2013-08-23 | 2014-01-01 | 内蒙古伊利实业集团股份有限公司 | Low-glycemic-index nutrient powder |
| CN104286849A (en) * | 2014-09-26 | 2015-01-21 | 上海励成营养产品科技股份有限公司 | Diabetes-specific enteral nutrition multi-polymerization agent |
-
2016
- 2016-10-09 CN CN201610879062.3A patent/CN107912776A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103478527A (en) * | 2013-08-23 | 2014-01-01 | 内蒙古伊利实业集团股份有限公司 | Low-glycemic-index nutrient powder |
| CN104286849A (en) * | 2014-09-26 | 2015-01-21 | 上海励成营养产品科技股份有限公司 | Diabetes-specific enteral nutrition multi-polymerization agent |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108523134A (en) * | 2018-05-04 | 2018-09-14 | 珠海津之敦医药科技有限公司 | A kind of avenabeta glucosan Orally administered composition and its application |
| CN108523134B (en) * | 2018-05-04 | 2021-12-24 | 珠海津之敦医药科技有限公司 | Oat beta-glucan oral composition and application thereof |
| CN110179107A (en) * | 2019-07-01 | 2019-08-30 | 北京东方倍力营养科技有限公司 | A kind of complete nutritional composition improving liver function and liver fibrosis |
| CN112273440A (en) * | 2020-09-16 | 2021-01-29 | 内蒙古欧世蒙牛乳制品有限责任公司 | Low-GI composition and low-GI milk powder with blood sugar balancing effect |
| CN115553457A (en) * | 2021-06-30 | 2023-01-03 | 杨劲松 | Food composition for regulating blood sugar metabolism |
| CN113951328A (en) * | 2021-11-30 | 2022-01-21 | 北安宜品努卡乳业有限公司 | A nutritional food for lowering blood sugar and reducing blood lipid, and its preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107912776A (en) | A kind of edible composition and its application for aiding in reducing the glycemic index of food | |
| CN101143010B (en) | Special-purpose nutritive food for diabetes patient and its preparation method | |
| CN103478527B (en) | A kind of nutritious powder for hypoglycemia patient | |
| CN102771797B (en) | All-round enteral nutrition preparation and preparation method thereof | |
| CN104286849A (en) | Diabetes-specific enteral nutrition multi-polymerization agent | |
| CN106962946B (en) | Method for constructing grain-like structure with slow digestibility | |
| MXPA02007627A (en) | Carbohydrate system and a method for providing nutriton to a diabetic. | |
| CN100577036C (en) | Use of pullulan as a slowly digested carbohydrate | |
| JPH1118725A (en) | Nutrient composition for diabetes patient | |
| CN104544432A (en) | Samara oil compound protein solid beverage and method for preparing same | |
| Ugwu | The potentials of roots and tubers as weaning foods | |
| Oku et al. | Evaluation of the relative available energy of several dietary fiber preparations using breath hydrogen evolution in healthy humans | |
| CN107951015A (en) | Full nutrient formulation powder and preparation method thereof | |
| CN103689375A (en) | Noodle formula suitable for diabetic patients and processing method of the noodle | |
| CN108125112A (en) | A kind of full nutrition infant diatery supplement and preparation method thereof | |
| CN103005261A (en) | Diet extender capable of restraining diabetic's blood sugar level from rising after meal | |
| CN107822116A (en) | Suitable for the ocean short peptide type special medicine purposes formula food of diabetic | |
| CN107048164A (en) | A kind of low sugar rice cake | |
| CN106901375A (en) | It is a kind of compound for sugar product containing xylitol | |
| CN105407740A (en) | Administration of a food composition product | |
| CN105285644A (en) | Vinegar beverage rich in dietary fiber and preparation method thereof | |
| EP3416502B1 (en) | Glycemic reducing composition | |
| CN114271335A (en) | Dairy product and method for producing the same | |
| CN108703378A (en) | A kind of fro diabetic many polymerizers of the EA | |
| CN104982768B (en) | A kind of jelly and preparation method thereof of suitable nephropathy patient's energy supplement |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |